Insider Selling: InVitae Corp (NVTA) VP Sells 2,497 Shares of Stock
InVitae Corp (NASDAQ:NVTA) VP Patty Dumond sold 2,497 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $10.00, for a total value of $24,970.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Patty Dumond also recently made the following trade(s):
- On Monday, October 9th, Patty Dumond sold 1,882 shares of InVitae Corp stock. The shares were sold at an average price of $10.00, for a total value of $18,820.00.
InVitae Corp (NVTA) traded up 0.10% during mid-day trading on Wednesday, hitting $9.95. The company had a trading volume of 233,223 shares. The stock’s market capitalization is $433.26 million. The stock has a 50 day moving average price of $9.36 and a 200-day moving average price of $9.36. InVitae Corp has a 1-year low of $5.76 and a 1-year high of $11.88.
InVitae Corp (NASDAQ:NVTA) last announced its earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The business had revenue of $14.34 million for the quarter, compared to analysts’ expectations of $13.31 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The firm’s quarterly revenue was up 157.0% compared to the same quarter last year. On average, analysts forecast that InVitae Corp will post ($2.35) earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in InVitae Corp by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 3,974,227 shares of the medical research company’s stock worth $43,955,000 after purchasing an additional 25,100 shares during the period. Vanguard Group Inc. raised its position in InVitae Corp by 9.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,323,137 shares of the medical research company’s stock worth $12,649,000 after purchasing an additional 116,871 shares during the period. ARK Investment Management LLC raised its position in InVitae Corp by 30.4% in the 2nd quarter. ARK Investment Management LLC now owns 982,170 shares of the medical research company’s stock worth $9,390,000 after purchasing an additional 229,189 shares during the period. State Street Corp raised its position in InVitae Corp by 43.1% in the 2nd quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock worth $5,528,000 after purchasing an additional 174,016 shares during the period. Finally, Northern Trust Corp raised its position in InVitae Corp by 39.0% in the 2nd quarter. Northern Trust Corp now owns 433,113 shares of the medical research company’s stock worth $4,140,000 after purchasing an additional 121,409 shares during the period.
A number of research analysts have recently issued reports on the company. Zacks Investment Research raised InVitae Corp from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research note on Wednesday. BidaskClub raised InVitae Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $15.00 price objective (up from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. InVitae Corp presently has a consensus rating of “Buy” and an average price target of $13.50.
InVitae Corp Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.